Loading…
NovoCure Limited is projected to rise to $17.48 by 2027, a +3% move from its current price of $16.99. NVCR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $16.40 | $16.98 | $17.58 | -0.05% |
| May 30 | $16.16 | $16.97 | $17.82 | -0.11% |
| May 31 | $15.98 | $16.96 | $18.01 | -0.16% |
| Jun 1 | $15.82 | $16.95 | $18.17 | -0.21% |
| Jun 2 | $15.69 | $16.94 | $18.31 | -0.27% |
| Jun 3 | $15.56 | $16.94 | $18.43 | -0.32% |
| Jun 4 | $15.45 | $16.93 | $18.55 | -0.37% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $15.45 | $16.93 | $18.55 | -0.37% |
| Week 2 | $14.82 | $16.86 | $19.19 | -0.74% |
| Week 3 | $14.34 | $16.80 | $19.68 | -1.11% |
| Week 4 | $13.94 | $16.74 | $20.09 | -1.48% |
| Week 5 | $13.59 | $16.68 | $20.46 | -1.85% |
| Week 6 | $13.28 | $16.61 | $20.78 | -2.21% |
| Week 7 | $13.00 | $16.55 | $21.08 | -2.58% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NovoCure Limited is an oncology company that develops, manufactures, and commercializes tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
NovoCure Limited (NVCR) trades at $17.96 per share and has a market cap of $2.08B. Its rank is 1974.
In the market snapshot, the forecast path shows a 2026 min of $10.03, an avg of $17.96, and a max of $24.99 with an ROI of 0%, followed by higher averages in subsequent years as sentiment remains neutral to bullish.
From 2028 onward, the outlook improves with 2028 avg $22.85 and 2029 avg $28.45, then advancing to 2030 avg $29.73 (ROI 65.6%), 2040 avg $52.95 (ROI 194.8%), and 2050 avg $125.28 (ROI 597.5%), reflecting a bullish longer-term trajectory.
Overall, the long-run forecast suggests upside potential, though these are estimates and not guarantees.
A major floor 44.9% below — a decisive break under it would weaken the trend.
The nearest floor, 29.8% below — buyers have tended to step in here.
The nearest ceiling, 7.8% above — a clean break opens room to run.
A major ceiling 30.2% above — clearing it would confirm fresh momentum.
Key NVCR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NVCR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $17.77 | Sell | $17.62 | Sell |
| MA 10 | $17.71 | Sell | $17.51 | Sell |
| MA 20 | $17.06 | Sell | $16.72 | Buy |
| MA 50 | $13.81 | Buy | $14.90 | Buy |
| MA 100 | $13.25 | Buy | $13.92 | Buy |
| MA 200 | $12.94 | Buy | $14.03 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.55 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -5.02 | Neutral |
| Williams %R (14) | -89.19 | Info |
| MACD (12,26,9) | -0.16 | Sell |
| ROC (12) | -5.03 | Sell |
| Bollinger %B (20,2) | 0.49 | Neutral |
| Stochastic %K (14) | 10.81 | Buy |
| TRIX (15) | 1.41 | Buy |
| Awesome (5,34) | 2.77 | Buy |
| Ultimate (7,14,28) | 47.88 | Neutral |
| Momentum (10) | -1.32 | Sell |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 17.90 | Sell |
| ADX (14) | 31.50 | Buy |
| ATR (14) | 0.49 | Info |
The 30-day technical picture is bullish with RSI14 at 70, indicating strong near-term momentum.
The stock’s moving-average backdrop shows SMA50 at $13.59 and SMA200 at $12.88, with clear support at $10.72 and resistance at $18.31.
The 30-day price range spans from $14.43 to $22.35, giving a sense of recent volatility within a defined band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $10.03 | $16.99 | $23.55 | 0% | Neutral | |
| $13.51 | $17.48 | $24.17 | +3% | Neutral | |
| $15.54 | $20.83 | $30.07 | +23% | Bullish | |
| $18.89 | $26.10 | $38.99 | +54% | Bullish | |
| $19.30 | $27.39 | $42.10 | +61% | Bullish | |
| $20.58 | $29.92 | $47.17 | +76% | Bullish | |
| $19.58 | $29.12 | $46.95 | +71% | Bullish | |
| $18.62 | $28.30 | $46.56 | +67% | Bullish | |
| $21.43 | $33.27 | $55.77 | +96% | Bullish | |
| $25.02 | $39.62 | $67.56 | +133% | Bullish | |
| $26.61 | $46.22 | $84.70 | +172% | Bullish | |
| $54.06 | $110.76 | $225.16 | +552% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $10.03 | $16.99 | $19.98 | +0.00% |
| June 2026 | $13.86 | $16.37 | $19.86 | -3.67% |
| July 2026 | $13.56 | $16.18 | $19.97 | -1.12% |
| August 2026 | $13.97 | $16.82 | $21.02 | +3.91% |
| September 2026 | $13.92 | $16.87 | $21.31 | +0.33% |
| October 2026 | $13.62 | $16.61 | $21.19 | -1.54% |
| November 2026 | $14.11 | $17.32 | $22.27 | +4.24% |
| December 2026 | $14.73 | $18.18 | $23.55 | +4.96% |
Click any year to see its month-by-month NVCR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, NVCR is projected to trade between $10.03 and $23.55, averaging $16.99 — a potential gain of 0% from today's $16.99. Price action looks broadly range-bound.
NovoCure Limited's 2027 outlook centres on $17.48, within a $13.51 to $24.17 range. That is up +3% on the projected 2026 average. That marks a +3% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, NVCR could reach as high as $30.07, with a base case around $20.83 and support toward $15.54 — roughly +23% from $16.99. Momentum favours further upside here.
Expect NVCR to range from $18.89 to $38.99 through 2029. The $26.10 average target implies a +54% move from current prices. That is up +25% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The NVCR price prediction for 2030 points to an average of $27.39 (low $19.30, high $42.10) — a potential gain of +61% on today's $16.99. Momentum favours further upside here.
In 2031, NVCR is projected to trade between $20.58 and $47.17, averaging $29.92 — a potential gain of +76% from today's $16.99. That is up +9% on the projected 2030 average. Buyers look set to stay in control over this stretch.
NovoCure Limited's 2032 outlook centres on $29.12, within a $19.58 to $46.95 range. That is -3% versus the projected 2031 average. That marks a +71% change versus current levels. Momentum favours further upside here.
By 2033, NVCR could reach as high as $46.56, with a base case around $28.30 and support toward $18.62 — roughly +67% from $16.99. Buyers look set to stay in control over this stretch.
Expect NVCR to range from $21.43 to $55.77 through 2034. The $33.27 average target implies a +96% move from current prices. That is up +18% on the projected 2033 average. Momentum favours further upside here.
The NVCR price prediction for 2035 points to an average of $39.62 (low $25.02, high $67.56) — a potential gain of +133% on today's $16.99. Buyers look set to stay in control over this stretch.
In 2040, NVCR is projected to trade between $26.61 and $84.70, averaging $46.22 — a potential gain of +172% from today's $16.99. That is up +17% on the projected 2035 average. Momentum favours further upside here.
NovoCure Limited's 2050 outlook centres on $110.76, within a $54.06 to $225.16 range. That is up +140% on the projected 2040 average. That marks a +552% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in NVCR today (≈ 58.858152 NVCR) could be worth
$6,519.07
+$5,519.07 (+552%) by 2050 · US Dollar
Based on the average projected NVCR price of $110.76 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NVCRwould be worth at today's price.
$1,000 invested in NVCR on May 27, 2025 (≈ 52.137643 NVCR) would be worth
$885.82
-$114.18 (-11.4%) today · 0.89× · US Dollar
Based on a NVCR entry price of $19.18 vs. today's $16.99.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $17.75 | $957.18 | -4.3% |
| 1 month ago | $12.48 | $1,361.38 | +36.1% |
| 3 months ago | $13.75 | $1,235.64 | +23.6% |
| 6 months ago | $12.81 | $1,326.31 | +32.6% |
| 1 year ago | $19.18 | $885.82 | -11.4% |
| All time (5.0y) ago | $202.61 | $83.86 | -91.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NVCR forecast.
Our base-case forecast reaches $34.00 around 2035.
Implied market cap at $34.00: $3.94B
The multi-year forecast highlights a bullish progression in average price and ROI. In 2030 the average price is projected at $29.73 with a 65.6% ROI, following a 2029 average of $28.45 and a 2028 average of $22.85.
The trajectory continues to 2040, where the average is $52.95 and ROI reaches 194.8%, and to 2050, with an average of $125.28 and ROI of 597.5%.
These figures imply meaningful upside potential over the coming decades, but they are estimates rather than guarantees and come with uncertainty.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $29.73 with a min of $21.15 and a max of $45.29, and a projected ROI of 65.6% with a bullish sentiment.
Forecasts indicate bullish sentiment from 2028 through 2050, with increasing average prices and ROI (e.g., 2028 avg $22.85, 2029 avg $28.45, 2030 avg $29.73 with 65.6% ROI; 2050 avg $125.28 with 597.5% ROI). Near-term years show neutral sentiment, but the longer-term outlook is bullish.
Yes. The 2031 forecast shows an avg of $32.82 with a min of $22.81 and a max of $51.22, implying that the average could exceed $30 in 2031.
Current price is $17.96 and market cap is $2.08B.
The 30-day range is $14.43 to $22.35. Technical sentiment is BULLISH, with RSI14 at 70, SMA50 at $13.59, SMA200 at $12.88, a support level of $10.72, and a resistance level of $18.31.
NovoCure Limited Community Discussion
0Share your NovoCure Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.